Why won't you give a single cost figure for building an API plant in Nigeria?

Because quoting Emzor's 23 million dollars as the cost of a Nigerian API plant would be misleading. That figure is one 400-tonne antimalarial facility with its own chemistry, scale and financing. A defensible estimate comes from applying the six cost drivers to your specific route and site, not from borrowing someone else's headline. A straight answer that is wrong is worth less than a range that is right.

Can I just adjust an Indian or Chinese API plant cost for Nigeria?

That shortcut is where most estimates go wrong. Indian and Chinese cost structures assume reliable grid power, mature utility and effluent services, deep local engineering talent and cheap capital. Remove those four and the number does not transfer. The Nigerian cost premium sits in the factors those benchmarks take for granted, so a flat-percentage adjustment buries the risks a financier will interrogate. Use them to understand process economics, not to price a Nigerian build.

If imported API is cheaper, why build an API plant in Nigeria at all?

On landed cost today, imported API is often cheaper for many products, and not every API is worth making in Nigeria. But that comparison prices only the molecule, not the exposure: it ignores foreign-exchange risk that has already forced manufacturers out, supply security, and the 5plus5 regulatory pressure. The right question is which specific APIs, at what scale, win locally once FX, supply risk and policy are priced in. A good study answers that selectively.

How much does it cost to build an API manufacturing plant in Nigeria?

Q: Isn't a cost analysis based on one plant just guesswork?

One plant is not a benchmark set, and anyone quoting a confident per-tonne Nigerian API cost is extrapolating from a single point or importing foreign assumptions. That is why the analysis relies on drivers rather than a headline: chemistry route, utilities, site, knowledge transfer, engineering and GMP standard determine cost and are knowable for a specific project even without market comparables. The rigour is in not pretending the number is more certain than the evidence allows.

Q: Will a capex estimate be obsolete once the naira moves?

A single naira-denominated figure has a short shelf life. But most of an API plant's capital cost is imported, dollar-denominated equipment, which is more stable than the naira headline suggests; volatility mainly hits local content and financing cost. A credible estimate models hard-currency and local-currency components separately and runs an explicit FX sensitivity, so it ages as a range rather than a point. The estimate that goes obsolete is the one collapsed into a single naira number.

There is no single number. Nigerian API plant capex is driven primarily by the chemistry route, and a petrochemical-derived synthesis plant, a biosimilars facility and a plant-extraction operation have fundamentally different cost structures. The one public benchmark available is Emzor’s antimalarial API facility in Sagamu, Ogun State with about a $23 million investment. Six factors impact that number more than anything else, and getting any one of them wrong can make the project unviable regardless of capex.
Author: Theodora Ogharanduku, CEO – Knectiv. Last reviewed: Aug 18, 2026

Start from the only public benchmark Nigeria has

Nigeria has effectively one dedicated API manufacturing facility: Emzor’s plant at Sagamu, focused initially on four antimalarial APIs - artemether, lumefantrine, sulfadoxine and pyrimethamine (Businessday). It is described as the first dedicated API facility of its kind in the region, with capacity of 400 metric tonnes annually, and was financed with a European Investment Bank loan covering up to 60% (€13.85 million) of a roughly $23 million project (EIB project record; Businessday).

Two things matter more than the headline figure.

First, the timeline. The plant originally targeted 2024 and moved to early 2026 operations, with the delay attributed to fiscal and regulatory headwinds (Billionaires Africa). Any Nigerian API capex budget that does not carry a serious contingency for schedule slippage is not a budget, it’s finger crossing. Time is money.

Second, the sample size. One facility is not a benchmark set in stone. Anyone quoting a confident per tonne cost for Nigerian API manufacturing is extrapolating from a single data point or importing Indian or Chinese cost assumptions that do not survive contact with Nigerian infrastructure, logistics and financing costs. Treat precision with suspicion.

The six factors that actually impact the number

1. Chemistry route - the single largest swing

API is not one thing, and this is where many cost estimates go wrong at the first step.

Petrochemical / synthetic route. Multi-step chemical synthesis. Heaviest requirements: solvent handling and recovery, containment, reactor trains, and critically, effluent treatment. Typically the highest capex and the most demanding environmental compliance burden.
Biosimilars. A different discipline entirely. Bioreactors, cold chain, sterile fill, and a far heavier analytical and quality control apparatus. Capital intensity and technical skill dependency are highest here.
Plant extraction. Lowest barrier of the three on process equipment, but introduces agricultural supply chain risk, raw material variability, and its own purification and standardisation challenges.

The practical implication ia that any capex question that hasn’t first specified the route is unanswerable. Decide the chemistry before you cost the plant.

2. Power and utilities - the make or break line items

This is the factor most likely to kill a Nigerian API business, and it is routinely treated as a footnote. GMP manufacturing requires uninterrupted, clean, stable power; purified water and Water for Injection systems; HVAC with validated air classification; and effluent treatment to environmental standard. In Nigeria, grid supply cannot be assumed, so the true cost includes generation redundancy, fuel exposure, and the operating cost of running utilities you would simlply buy in more stable environments.

The consequence is that utilities are not just a line item in the capex - they are a permanent structural feature of the opex and therefore of the unit economics. A plant that is affordable to build and uneconomic to run is the most common failure mode in this sector.

3. Location (and yes, it is king)

Site selection determines utility access and cost, logistics distance to ports and inputs, effluent discharge feasibility, state-level incentives and the speed of regulatory and land processes, and access to a technical labour pool. Two sites with identical engineering designs can differ enormously in both delivered capex and lifetime opex. Location is not a late stage decision to be optimised after the design is fixed; it is an upstream determinant of whether the business case closes at all.

4. Knowledge transfer - the cost nobody budgets

Nigeria does not currently have a deep domestic pool of API process chemistry, GMP qualification and validation expertise. That capability has to be imported and transferred, through technology transfer or licensing arrangements, expatriate technical leadership, structured training, and partnership with established manufacturers or research institutions.

This is a real, recurring, and frequently underestimated cost. Treating it as a soft “training” line rather than a core project workstream is one of the clearest signals to a development finance institution that a project is not ready. A credible project names its knowledge transfer partner and its plan.

5. The engineering and construction partner

Pharmaceutical and life sciences construction is a specialist discipline, not general industrial build. Cleanroom construction and classification, qualification and validation documentation, and design that anticipates a GMP inspection are not skills a competent general contractor acquires on the job. Appointing a partner without genuine pharma or life sciences credentials is one of the most expensive mistakes available, because the remediation cost lands after construction, when it’s at its most painful, and it directly threatens the compliance outcome the entire investment depends on.

For the same reason, the identity and track record of the engineering partner is itself a bankability signal to a DFI.

6. WHO GMP compliance - the factor that determines whether the plant is worth building

This is the decisive one, and it should be decided at design stage, not discovered at inspection.

If a facility is not built to WHO GMP standard, its addressable market is effectively the Nigerian domestic market alone. That single fact reshapes the entire investment case - it caps revenue, removes access to donor-funded and regional procurement, forecloses meaningful export effectively weakening the project’s attractiveness to development finance.

Swiss Pharma is Nigeria’s only WHO GMP certified pharmaceutical products manufacturer, and is the first and currently the only one in West and Central Africa to secure WHO prequalification.

Building to WHO GMP costs more upfront in design, materials, systems, documentation and qualification. Not building to it costs the business its potential market, which isn’t just domestic. The upgrade path from a non-compliant facility is generally far more expensive than designing for compliance from the outset, and often practically impossible without substantial rebuild.

If the project cannot reach WHO GMP, the honest recommendation is usually not to build.

What a credible cost estimate looks like

A number you can take to a financier is not just a capex figure. It’s a capex figure that is attached to a defined chemistry route, a specific site with verified utility and effluent conditions, a named engineering partner with life sciences credentials, a funded knowledge transfer plan, a WHO GMP design standard, and a contingency that reflects Nigerian schedule risk. If any of those are absent, the number is decoration.

Where Genesis Science Park fits

The largest and least controllable cost drivers above - power and utilities, effluent, site conditions, GMP-grade infrastructure - are precisely the ones an IaaS life sciences park moves off a single manufacturer’s balance sheet and onto shared, purpose built infrastructure. Removing these from capex not only reduces how much investment is required, thereby reducing a project’s risk profile, but it saves 100+ hours on the feasibility study so the focus can be on the chosen chemistry route and knowledge transfer - the actual business of active ingredients formulation.

→ Express your interest and download the technical prospectus.

For manufacturers that are undertaking a feasibility study, or are operational and expanding.

FAQs

You spent the page insisting there’s no single number, then gave me Emzor at $23 million. Which is it, are you dodging the question?

A fair point but quoting Emzor’s $23 million as "the cost of a Nigerian API plant" would be the real dodge. That figure is for one 400 tonne antimalarial facility with its own chemistry, scale and financing; treat it as the definitive number and projects will be budgeted the wrong. The page gives the one genuine, EIB verified data point that exists, then refuses to over generalise it, because a defensible estimate comes from applying the six cost drivers to a projects route and site, not from borrowing someone else’s headline. A straight answer that’s wrong is worth less than a range that’s right.

Basing an entire cost analysis on one plant is guesswork dressed up as rigour. Why should I trust it?

It’s true that one sole plant is not a benchmark set, and anyone quoting a confident per tonne Nigerian API cost is extrapolating from a single point or importing foreign assumptions. That is exactly why the analysis leans on drivers rather than a headline: chemistry route, utilities, site, knowledge transfer, engineering and GMP standard are what determine cost, and these are knowns for every specific project even when the market lacks comparables. The rigour is not in the number, it’s in refusing to pretend the number is more certain than the evidence allows.

Why not just take an established Indian or Chinese API plant cost and adjust it for Nigeria?

That is the shortcut most estimates take, and it’s where most of them go wrong. Indian and Chinese cost structures assume reliable grid power, mature effluent and utility services, deep local engineering talent and cheap capital, remove those four and the number doesn’t survive the assumption. The Nigerian cost premium sits almost entirely in the factors those benchmarks take for granted, so adjusting a foreign figure by a flat percentage buries the very risks a financier will interrogate. Use them to understand process economics, not to price a Nigerian build.

If a Nigerian plant costs this much and imported API is cheaper, why build locally at all?

On landed cost today, for many products, imported API often is cheaper and the honest conclusion is that not every API is worth making in Nigeria. But that comparison prices only the molecule, not the exposure: it ignores the FX risk that has already forced manufacturers out, supply security, and the 5+5 pressure that is changing what "cheaper" means. The right question is not "is local API cheaper than imported?" but "for which specific APIs, at what scale, does local production win once FX, supply risk and policy are priced in?" A good cost study answers that selectively, not ideologically.

The Naira can move 30% in a year. Won’t any capex estimate be obsolete before I break ground?

A single Naira denominated figure has a short shelf life, so it’s right to distrust one. But most of an API plant’s capital cost is imported, dollar denominated equipment, which is far more stable than the naira headline suggests. The volatility mainly hits local content and financing cost. A credible estimate therefore models hard currency and local currency components separately and runs an explicit FX sensitivity, so the figure ages as a range rather than a point. The estimate that goes obsolete is the one that collapsed everything into a single naira number in the first place.